权衡利弊：慢性淋巴细胞白血病中的微小残留病
Measure for measure: minimal residual disease in CLL.
作者信息
Little Richard F, McShane Lisa M
机构信息
NATIONAL INSTITUTES OF HEALTH.
出版信息
Blood. 2016 Dec 15;128(24):2747-2748. doi: 10.1182/blood-2016-11-745323.
Abstract
In this issue of , Kwok and colleagues have provided a wealth of retrospective clinical data that greatly expands our appreciation for the prognostic importance of flow-cytometric residual disease measurement across a spectrum of clinical presentations in chronic lymphocytic leukemia (CLL).
摘要
在本期《 》中，郭及其同事提供了大量回顾性临床数据，极大地扩展了我们对慢性淋巴细胞白血病（CLL）各种临床表现中流式细胞术残留病测量的预后重要性的认识。
相似文献
1
Measure for measure: minimal residual disease in CLL.权衡利弊：慢性淋巴细胞白血病中的微小残留病
Blood. 2016 Dec 15;128(24):2747-2748. doi: 10.1182/blood-2016-11-745323.
2
[Analysis of immunophenotype characteristics in 109 cases of B lineage chronic B lymphoid leukemia].109例B淋巴细胞慢性淋巴细胞白血病免疫表型特征分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Dec;19(6):1374-7.
3
Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.用于通过流式细胞术灵敏检测B细胞慢性淋巴细胞白血病微小残留病的八色单管检测法的优化与验证
Lab Med. 2016 May;47(2):103-11. doi: 10.1093/labmed/lmw006.
4
CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.B细胞慢性淋巴细胞白血病中CD79b的表达：其在微小残留病检测中的意义。
Leukemia. 1999 Oct;13(10):1501-5. doi: 10.1038/sj.leu.2401511.
5
Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia.散发性和家族性慢性淋巴细胞白血病的定义与诊断
Hematol Oncol Clin North Am. 2004 Aug;18(4):783-94, vii. doi: 10.1016/j.hoc.2004.04.009.
6
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.多参数流式细胞术和高通量测序在慢性淋巴细胞白血病微小残留病检测中的互补作用：一项欧洲慢性淋巴细胞白血病研究倡议。
Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.
7
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.467例B细胞慢性淋巴细胞增殖性疾病患者的表型异常发生率：用于微小残留病研究的特定四色染色设计基础
Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584.
8
The detection of minimal residual disease status in chronic lymphocytic leukemia.慢性淋巴细胞白血病微小残留病状态的检测
Cytometry B Clin Cytom. 2011 Nov;80(6):344-5. doi: 10.1002/cyto.b.20625.
9
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.慢性淋巴细胞白血病患者的微小残留病监测。流式细胞术与 ASO IgH RQ-PCR 的比较分析。
Br J Haematol. 2014 Aug;166(3):360-8. doi: 10.1111/bjh.12887. Epub 2014 Apr 16.
10
Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.在常规血液学实践中使用8色流式细胞术方案检测慢性淋巴细胞白血病患者的微小残留病。
Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13.
引用本文的文献
1
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.微小残留病作为儿童急性淋巴细胞白血病无事件生存替代终点的验证
JNCI Cancer Spectr. 2018 Dec 19;2(4):pky069. doi: 10.1093/jncics/pky069. eCollection 2018 Oct.
本文引用的文献
1
The 21st century revolution in CLL: Why this matters to patients.21世纪慢性淋巴细胞白血病的变革：为何这对患者至关重要。
Best Pract Res Clin Haematol. 2016 Mar;29(1):122-132. doi: 10.1016/j.beha.2016.08.008. Epub 2016 Aug 11.
2
Minimal residual disease is an independent predictor for 10-year survival in CLL.微小残留病是 CLL 患者 10 年生存的独立预测因子。
Blood. 2016 Dec 15;128(24):2770-2773. doi: 10.1182/blood-2016-05-714162. Epub 2016 Oct 3.
3
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.微小残留病灶评估改善慢性淋巴细胞白血病（CLL）患者达部分缓解患者的预后预测：德国 CLL 研究组两项 III 期研究的综合分析。
J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.
4
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.将清除微小残留病作为治疗终点：致力于实现慢性淋巴细胞白血病患者的治愈
Blood. 2016 Jan 21;127(3):279-86. doi: 10.1182/blood-2015-08-634816. Epub 2015 Nov 17.
5
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.临床研究中的统计学争议：将病理完全缓解评估为早期乳腺癌试验水平的替代终点
Ann Oncol. 2016 Jan;27(1):10-5. doi: 10.1093/annonc/mdv507. Epub 2015 Oct 21.
6
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.伊布替尼治疗期间持续的淋巴细胞增多与独特的分子特征相关，并不表明对治疗的反应不佳。
Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10.
7
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?微小残留病灶检测在 CLL 治疗中的作用：是否已准备好成为主流？
Hematol Oncol Clin North Am. 2013 Apr;27(2):267-88. doi: 10.1016/j.hoc.2013.01.005.
8
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.微小残留病灶定量是慢性淋巴细胞白血病无进展和总生存的独立预测因子：来自随机 GCLLSG CLL8 试验的多变量分析。
J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.
9
Biomarkers and surrogate end points--the challenge of statistical validation.生物标志物和替代终点——统计验证的挑战。
Nat Rev Clin Oncol. 2010 Jun;7(6):309-17. doi: 10.1038/nrclinonc.2010.43. Epub 2010 Apr 6.
10
Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.慢性淋巴细胞白血病干细胞移植后，通过不同技术评估的微小残留病的临床意义。
Blood. 2006 Jun 1;107(11):4563-9. doi: 10.1182/blood-2005-09-3634. Epub 2006 Jan 31.
Zotero 插件